The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1450118
Mycobacterium w -a promising immunotherapeutic intervention for diseases
Provisionally accepted
Kirsten Stefan
1
Ryan Gordon
1*
Annah Rolig
1*
Alexander Honkala
1*
Dhanir Tailor
1
Lara E. Davis
1
Rajiv I. Modi
2*
Manjul Joshipura
2*
Bakulesh Khamar
2*
Sanjay V. Malhotra
1*- 1 Oregon Health and Science University, Portland, United States
- 2 Cadila Pharmaceuticals Ltd, Dholka, India
Immunomodulating agents interact with the immune system and alter the outcome of specific immune processes. As our understanding of the immune system continues to evolve, there is a growing effort to identify agents with immunomodulating applications to use therapeutically to treat various diseases. Mycobacterium w (Mw), a heat-killed mycobacterium, is an atypical mycobacterial species that possesses strong immunomodulatory properties. Mw was initially evaluated as an immune-therapeutic against leprosy, but since then Mw has generated a lot of interest and been studied for therapeutic applications across a host of diseases, such as pulmonary tuberculosis, tuberculous pericarditis, sepsis, lung cancer, and more. This article summarizes a large body of work published in the past five decades, describing various aspects of Mw and its potential for further therapeutic development.
Keywords: immune therapy, Mycobacterium w, Vaccine, Leprosy, Cancer, Tuberculosis, COVID-19
Received: 16 Jun 2024; Accepted: 02 Oct 2024.
Copyright: © 2024 Stefan, Gordon, Rolig, Honkala, Tailor, Davis, Modi, Joshipura, Khamar and Malhotra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ryan Gordon, Oregon Health and Science University, Portland, United States
Annah Rolig, Oregon Health and Science University, Portland, United States
Alexander Honkala, Oregon Health and Science University, Portland, United States
Rajiv I. Modi, Cadila Pharmaceuticals Ltd, Dholka, India
Manjul Joshipura, Cadila Pharmaceuticals Ltd, Dholka, India
Bakulesh Khamar, Cadila Pharmaceuticals Ltd, Dholka, India
Sanjay V. Malhotra, Oregon Health and Science University, Portland, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.